[Vascular pleiosynergism--a new concept?]

Area of Science:

• Cardiovascular medicine
• Pharmacology
• Molecular biology

Background:

• Cardiovascular risk factors amplify risk exponentially, necessitating effective parallel treatments.
• Drug classes exhibit varied efficacy due to distinct primary and pleiotropic effects.
• Pleiotropic effects, or "side" effects with therapeutic benefits, are increasingly important.

Purpose of the Study:

• To explore the pleiotropic profiles of statins and amlodipine.
• To investigate the molecular mechanisms underlying their combined therapeutic efficacy.
• To define and evaluate "pleiosynergism" in cardiovascular drug therapy.

Main Methods:

• Review of molecular biological data on statins and amlodipine.
• Analysis of their effects on endothelial nitrogen-monoxide (NO) synthesis, reactive oxygen species, and smooth muscle cell migration/proliferation.
• Examination of the ASCOT-LLA trial data comparing drug regimens.

Main Results:

• Statins and amlodipine share pleiotropic effects, including enhanced endothelial NO synthesis and reduced smooth muscle cell proliferation.
• Both drugs influence the caveolin/eNOS complex, increasing eNOS activity.
• The ASCOT-LLA trial showed a 3.3x greater benefit for atorvastatin/amlodipine over atorvastatin/atenolol, suggesting pleiosynergism.

Conclusions:

• Pleiosynergism between statins and amlodipine, driven by shared molecular targets, significantly enhances cardiovascular protection.
• This interaction offers greater therapeutic efficacy than additive effects alone.
• Combination therapy with statins and amlodipine presents a potent strategy for managing cardiovascular risk.